Liquid Biopsy Market, Analysis by Players, Size, Competitive Analysis, 2004Posted by Yash Chauhan on March 4th, 2019
The global liquid biopsy market is growing at a significant rate, due to the mounting occurrence of cancer, and escalating emphasis on personalized medicine. Different product and services such as assay kits, services, and instruments contributed to the global market size. The market has witnessed a high demand for assay kits due to mounting need for biopsy tests, the necessity for dependable and precise assays, and escalating applications of liquid biopsies. Request for sample copy of this research report at: https://www.vynzresearch.com/healthcare/liquid-biopsy-market/request-sample The mounting mergers and acquisition, strengthening product offerings, and improving geographic presence are the major trends of the liquid biopsy market. For instance, in January 2017, Bio-Rad Laboratories, Inc. signed an agreement to acquire RainDance Technologies, Inc. to strengthen its position in next-generation sequencing application. The mounting occurrence of cancer, escalating emphasis on personalized medicine, intensifying inclination for noninvasive procedures, and availability of finance for research and development are the primary growth drivers for liquid biopsy market. Asia-Pacific is observed to witness the fastest growth in the liquid biopsy market due to the mounting occurrence of cancer, and escalating disposable income in the region. Biocept, Inc., Roche Diagnostics, Trovagene, Inc., Illumina, Inc., QIAGEN N.V., Menarini-Silicon Biosystems, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Genomic Health, Inc., Guardant Health, Inc., and MdxHealth SA are the key players offering liquid biopsy products. Source: VynZ Research Like it? Share it! More by this author |
